Antifungal Drug Therapy | Chapter 42 – Brenner & Stevens’ Pharmacology (6th)

Описание: This chapter delves into the specialized field of medical mycology and the pharmaceutical agents designed to combat various fungal pathogens. It begins by categorizing fungal infections, or mycoses, based on their clinical presentation and depth of tissue involvement, distinguishing between superficial mucocutaneous infections affecting keratinized tissues like skin and nails, subcutaneous infections resulting from traumatic inoculation into deeper tissues, and potentially life-threatening systemic infections involving internal organs. A primary focus of the discussion is the distinct biochemical differences between fungal and mammalian cells, particularly the presence of ergosterol in fungal membranes instead of cholesterol, which serves as a vital target for selective toxicity. Polyene antibiotics, such as amphotericin B and nystatin, function by binding directly to this ergosterol, creating pores that lead to lethal cell leakage; however, the systemic use of amphotericin B is notoriously limited by severe renal toxicity, though newer lipid-based formulations have significantly improved its safety profile by altering drug distribution. Azole derivatives, categorized into imidazoles and triazoles, work by inhibiting the fungal cytochrome P450 enzyme 14-alpha-demethylase, thereby halting the biosynthesis of ergosterol. This extensive group includes widely used agents like fluconazole, which is prized for its excellent cerebrospinal fluid penetration for treating fungal meningitis, and second-generation triazoles like voriconazole that offer enhanced activity against resistant molds such as Aspergillus. The chapter also introduces the echinocandin class, featuring drugs like caspofungin, which uniquely target the fungal cell wall by inhibiting the synthesis of beta-1,3-D-glucan, providing a highly effective and well-tolerated option for invasive candidiasis. Furthermore, the text covers allylamines like terbinafine, which are essential for treating stubborn nail infections, the antimetabolite flucytosine which interferes with fungal RNA and protein synthesis when used in combination therapy, and the mitotic inhibitor griseofulvin, which is specifically used for scalp and skin dermatophytes. Understanding these diverse mechanisms, along with their unique pharmacokinetic profiles and potential drug-drug interactions involving human hepatic enzymes, is essential for effectively managing fungal diseases in both healthy and immunocompromised patient populations.


📘 Read full blog summaries for every chapter:
https://lastminutelecture.com

📘 Have a book recommendation? Submit your suggestion here:
https://forms.gle/y7vQQ6WHoNgKeJmh8

Thank you for being a part of our little Last Minute Lecture family!

⚠️ Disclaimer: These summaries are created for educational and entertainment purposes only. They provide transformative commentary and paraphrased overviews to help students understand key ideas from the referenced textbooks. Last Minute Lecture is not affiliated with, sponsored by, or endorsed by any textbook publisher or author. All textbook titles, names, and cover images—when shown—are used under nominative fair use solely for identification of the work being discussed. Some portions of the writing and narration are generated with AI-assisted tools to enhance accessibility and consistency. While every effort has been made to ensure accuracy, these materials are intended to supplement—not replace—official course readings, lectures, or professional study resources. Always refer to the original textbook and instructor guidance for complete and authoritative information.